Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 with Chemoradiation in Pancreatic Adenocarcinoma
NCT05325281Phase 1Terminated
- Sponsor
- Medical College of Wisconsin
- Start
- Oct 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of devimistat in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Maximum Tolerated Dose of CPI-613 at 30 days. Started Oct 2022; status: terminated.
02
Drugs
devimistat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05325281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325281.